[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anxiety-and-depression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anxiety-and-depression":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,76,111,135,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100581690","pharmacogenetic-guided-antidepressant-prescribing-in-adolescents-with-anxiety-and-depression-100581690",false,"NCT06853587","Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression","PGx-GAP","Inclusion Criteria:\n\n* Age 12-17\n* Depression and\u002For anxiety as the primary concern, confirmed by the treating physician\n* Intention to start a new SSRI\n* English fluency\n\nExclusion Criteria:\n\n* Co-occurring obsessive compulsive disorder, psychosis, bipolar disorder, eating disorder, autism spectrum disorder, fetal alcohol spectrum disorder, or intellectual disability\n* History of non-response to 3 or more SSRI medications as confirmed by the treating physician\n* Brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate\u002Fchange brain stimulation during study participation\n* History of liver or hematopoietic cell transplant\n* History of CYP2B6, CYP2C19, or CYP2D6 testing","ALL","12 Years","17 Years",{"count":20,"type":21},228,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=228) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression and\u002For anxiety will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or current prescribing guidelines\u002Frecommendations guided therapy (control intervention).",[27],"Anxiety and Depression",[29,30,31,32,33,34],"depression","anxiety","adolescence","SSRI","antidepressant","pharmacogenetics","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-22","ACTUAL",{"date":41,"type":39},"2025-02-11",{"date":43,"type":21},"2027-12",{"name":45,"class":46},"University of Calgary","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":47},"100530603","phase-2-a-new-intervention-to-improve-function-in-veterans-with-anxiety-and-depression-100530603","NCT06188923","A New Intervention to Improve Function in Veterans With Anxiety and Depression","Inclusion Criteria:\n\n* Veterans enrolled for care at the Durham VAHCS\n* Veterans who score a minimum score of 20 or higher (moderate symptoms) on the PHQ-ADS (Kroenke et al 2017)\n* Oral pregnenolone could reduce the effectiveness of oral contraceptives, thus women will be required to use a medically and study-approved contraceptive or otherwise not be of child-bearing potential. Birth control methods must be non-hormonal\n* No anticipated need to alter psychiatric medications for duration of study involvement\n* Ability to participate fully in the informed consent process\n\nExclusion Criteria:\n\n* History of allergy to PREG\n* Medical disorders that may preclude safe administration of PREG or exacerbate mental or physical health symptoms\n* PTSD diagnosis, as per the PCL-5, scores of 38 or higher\n* Current suicidal or homicidal ideation necessitating clinical intervention or representing an imminent concern\n\n  * Prior attempts or suicidal ideation that does not require clinical intervention or represent an imminent concern is permitted\n* Serious unstable medical illness, such as history of cerebrovascular accident, prostate, uterine or breast cancer, others (at the discretion of the PI and medical oversight team)\n* Standard pharmacological interventions for mental health disorders will not be exclusionary; however, there may be no changes in psychotropic medications for mental or physical health conditions 4 weeks prior to study randomization\n* Benzodiazepine or opioid use\n* Current diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition other than mild TBI (assessed at screening)\n* Initiation or change in psychotherapy within 3 months of randomization (i.e., psychotherapy must be stable for 3 months prior to study start\n* Due to lack of safety data in pregnant and breast-feeding women, female participants who are pregnant or breast-feeding will be excluded\n* As indicated by the DSM-5, moderate or severe Substance Use Disorders (excluding caffeine and tobacco) within 1 month of study entry","18 Years","65 Years",{"count":57,"type":21},84,[59],"PHASE2","Anxiety and depression symptoms occur at high rates in Veteran populations and can significantly impact function, compromising the ability to work and to successfully form and maintain valued relationships. Several other symptoms commonly occur with anxiety and depression, including poor sleep quality and chronic pain. Since all these symptoms frequently occur together, they may have a common underlying biological basis. A single medication that could effectively treat all these symptoms would be ideal. Converging data suggest that pregnenolone is a promising pharmacological agent for treating multiple psychiatric symptoms and functional impairment. The investigators thus propose to conduct a clinical trial of pregnenolone in Veterans with anxiety and depression symptoms. Pregnenolone has minimal side effects, and the prior research demonstrates that pregnenolone is well-tolerated by Veterans. Treatment with pregnenolone could thus be an efficacious new therapeutic for Veterans experiencing depression, anxiety, poor sleep quality and chronic pain conditions.",[27],[63,30,29,64,65],"pregnenolone","pain","sleep","2026-04-20",{"date":68,"type":39},"2026-04-23",{"date":70,"type":39},"2025-08-14",{"date":72,"type":21},"2028-09-30",{"name":74,"class":75},"VA Office of Research and Development","FED",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":95,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":47},"100606160","effects-of-artificial-intelligence-nurse-orientation-program-on-psychological-outcomes-and-length-of-hospital-stay-in-intensive-care-unit-100606160","NCT07171944","Effects of Artificial Intelligence Nurse Orientation Program on Psychological Outcomes and Length of Hospital Stay in Intensive Care Unit","Effects of AINurse Orientation Program on Psychological Outcomes and Length of Hospital Stay: A Randomized Controlled Trial","AINURSE-OP","Inclusion Criteria:\n\n* Intensive care unit confusion assessment scale (CAM-ICU scale) score of 0-2\n* Age 18 years or older\n* Hospitalized in the intensive care unit for at least 24 hours\n* Glasgow coma scale score of 13-14-15 points\n* Richmond Agitation Sedation Scale (RASS) score between -1 and +1\n* No hearing problems\n\nExclusion Criteria:\n\n* Intensive care unit confusion assessment scale (CAM-ICU scale) score of 6-7\n* Any psychiatric illness or impaired brain function\n* Defined hearing loss\n* Advanced dementia\n* Younger than 18 years of age\n* Richmond Agitation Sedation Scale (RASS) score outside the range of -1 to +1\n* Who use sedative medication\n* History of surgery or disease around the ear",{"count":85,"type":21},10,[24],"Artificial intelligence (AI), now an integral part of healthcare services and presents numerous opportunities. Customized treatment plans, clinical decision support systems, predictive analysis for disease prevention, patient engagement and education, quality improvement, and error reduction are some of these opportunities. In the context of delirium prevention, risk assessment, and treatment planning, the AI-supported system AI-AntiDelirium is designed to standardize the approach to delirium management in alignment with the PADIS guidelines. A randomized controlled trial evaluating the effectiveness of this system found that the workload of nurses decreased, facilitated early diagnosis and prevention of delirium, and recommended evidence-based and individualized delirium interventions. A systematic review concluded that AI applications did not significantly impact the length of hospital stay and emphasized the need for further research. Also, AI platforms contributed to positive results in reducing anxiety and depression in patients. Furthermore, systematic reviews have demonstrated that AI-based chatbots are effective in alleviating symptoms of depression and anxiety. However, the literature includes a limited number of patient education programs specifically designed to prevent or manage delirium through AI-based approaches. Notably, there is a lack of studies comparing the effectiveness of AI-supported educational interventions with those delivered directly by nurses.\n\nThe goal of this clinical trial is to develop a structured AINurse and Human Nurse orientation training program for intensive care unit (ICU) patients and compare the effects of these training programs on ICU patients' delirium-free days, level of anxiety and depression, and length of stay in the ICU. Hypotheses of the study:\n\nH1: Patients who receive the structured AINurse patient orientation training program will have longer delirium-free days than patients who receive Human Nurse orientation training.\n\nH2: Patients who receive the structured AINurse patient orientation training program will have lower levels of anxiety and depression than patients who receive the Human Nurse orientation training.\n\nH3: Patients who receive the structured AINurse patient orientation training program will have shorter lengths of stay in the intensive care unit than patients who receive the Human Nurse orientation training.\n\nResearchers will compare the AINurse patient orientation training program and the orientation training program provided by human nurses in terms of patients' delirium-free days, level of anxiety and depression, and length of stay in the ICU.\n\n* Those in the intervention group will receive the AINurse orientation training program twice daily for 3 days.\n* Participants in the control group will receive face-to-face structured orientation training from researchers twice daily for 3 days.\n* Delirium-free day assessment, anxiety and depression will be evaluated for patients in both groups over 3 days.\n* The length of stay in the intensive care unit will be monitored for patients in both groups.",[89,27,90,91,92,93,94],"Delirium","Intensive Care Units (ICUs)","Artificial Intelligence (AI)","Nurse","Critical Care","Orientation",[89,96,97,98,99,100,92],"Artificial intelligence","Anxiety and depression","Intensive care unit","critical care","Orientation Training","NOT_YET_RECRUITING","2025-09-10",{"date":104,"type":39},"2025-09-15",{"date":106,"type":21},"2025-11-01",{"date":108,"type":21},"2026-11-01",{"name":110,"class":46},"Koç University",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":118,"minAge":54,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":47},"100592509","acupuncture-for-anxiety-and-depression-100592509","NCT06994351","Acupuncture for Anxiety and Depression","The Effects of Acupuncture on Anxiety and Depression of Patients With Breast Cancer","Inclusion criteria\n\n1. Female, aged 18 to 70 years old;\n2. Meeting the diagnostic criteria for breast cancer and at TMN I-III;\n3. Having completed specialized active treatment for at least one month;\n4. With an ECOG score of 0-2;\n5. Mild to moderate anxiety and\u002For depression;\n6. Voluntarily joining this study and signing the informed consent form. Exclusion criteria\n\n(1) Starting to take or change the regimen of anti-anxiety and\u002For -depression disorder medication within one month before enrolment; (2) Received psychological intervention or physical therapy one month before enrolment or planning to use in the next 5 months; (3) With diagnosis of anxiety and\u002For depression disorder prior to the diagnosis of breast cancer; (4) Patients with suicidal tendencies, bipolar disorder and psychotic symptoms; (5) Patients with severe anxiety and\u002For depression； (6) Patients received acupuncture treatment within one month before enrolment; (7) Participating in other clinical studies on the treatment of anxiety and depression; (8) Combined with severe underlying diseases; (9) Patients with severe skin ulcers; (10) Pregnant or lactating patients; (11) Poor compliance.","FEMALE","70 Years",{"count":121,"type":21},20,[24],"The study aims to primarily investigate the effects and safety of acupuncture on anxiety and depression among patients with breast cancer.",[27,125],"Breast Cancer Survivor","2025-05-25",{"date":128,"type":39},"2025-05-29",{"date":130,"type":21},"2025-05-18",{"date":132,"type":21},"2025-12-31",{"name":134,"class":46},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":47},"100566178","feasibility-and-acceptability-of-group-medical-visits-for-anxiety-and-depression-100566178","NCT06651801","Feasibility and Acceptability of Group Medical Visits for Anxiety and Depression","A Pilot Randomized Controlled Trial Assessing the Feasibility and Acceptability of Group Medical Visits for Anxiety and Depression","Inclusion Criteria:\n\n* Adult Central Intake patients (patients referred for psychiatric consultation by their primary care provider) whose primary mental health issue is an anxiety disorder (social anxiety, generalized anxiety, or panic disorder) or depression (major depressive disorder or persistent depressive disorder)\n* Able to participate in English language group with up to 10 participants\n* Able to commit to a virtual biweekly group for about 1.5 hours each group\n* Able to do virtual group from a private location with camera access\n* Live in community in Manitoba and plan to stay for 6-month period\n\nExclusion Criteria:\n\n* Patients with Bipolar 1 or 2 Disorder (even if current episode depression)\n* Primary diagnosis of a personality disorder leading to anxiety\u002Fdepression symptoms (personality disorder traits are not an exclusion criteria)\n* Patients who already have established longitudinal care with a psychiatrist\n* Received ECT treatment within past 6 months\n* Any diagnosis that would significantly impact ability to participate in the group. For example:\n* Moderate-to-severe substance use disorders (in particular substance use throughout day or inability to attend group without using substances before)\n* Current psychotic symptoms\n* Moderate-to-severe intellectual disability or neurocognitive disorder\n* Current significant eating disorder symptoms (for example resulting in significant weight loss\u002Fmalnutrition or that take up a significant part of the day either mentally or physically)\n* Self harm behaviour requiring medical\u002Fpsychiatric attention or active suicidal ideation\u002Fsuicide attempts within the past 6 months\n* Concern about safety of other group members\u002Ffacilitators if this patient were to join",{"count":121,"type":21},[24],"The goal of this clinical trial is to evaluate the feasibility and acceptability of the intervention, Group Medical Visits (GMVs), for patients with depression and anxiety. It also aims to get some initial information on the effectiveness of GMVs on reducing depression and anxiety scores, which will help inform power calculations for a future larger randomized controlled trial (RCT). The main question it aims to answer is:\n\n* Are GMVs feasible and acceptable to patients with depression and anxiety?\n\nThis study consists of a pilot RCT with an intervention and control arm. At enrollment, participants will be randomized to the intervention group, 6 months of GMVs, or to the control group, which consists of \"standard client services\". For the GMV group, participants will engage in a biweekly virtual group that is similar to a standard psychiatric follow-up. Participants in the control group will receive standard care after a psychiatric assessment, which includes follow-up with their primary care provider (family physician or nurse practitioner), individual psychiatric care if suggested by the psychiatrist who did their psychiatric assessment, and\u002For a referral to publicly funded therapy groups if interested.",[146,27,147],"Mental Health Care","Pilot Study",[149,150,151,152,147],"Group Medical Visits","Anxiety","Depression","Shared Medical Appointments","2025-05-09",{"date":155,"type":39},"2025-05-13",{"date":157,"type":39},"2025-04-15",{"date":159,"type":21},"2025-11",{"name":161,"class":46},"University of Manitoba",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":118,"minAge":54,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":47},"100525059","the-effects-of-laughter-yoga-and-mindfulness-based-stress-reduction-mbsr-practices-applied-to-women-with-breast-cancer-100525059","NCT06116812","The Effects of Laughter Yoga and Mindfulness-Based Stress Reduction (MBSR) Practices Applied to Women With Breast Cancer","The Effects of Laughter Yoga and Mindfulness-based Stress Reduction (MBSR) Practices Applied to Women With Breast Cancer Receiving Chemotherapy on Anxiety, Depression, Quality of Life and Spiritual Well-being Levels: A Randomized Controlled Study","Inclusion Criteria:\n\n* Women who are 18 years of age or older, do not have communication problems, have and can use a smartphone, do not have internet problems to participate in group sessions, volunteer to participate in the study, receive chemotherapy at least once a month and will continue to receive chemotherapy during the study. Women with stage 1 and stage 2 breast cancer, women with primary and secondary education, women within the first year of treatment in terms of the number of cycles, women with a score of 8 or more on the Hospital anxiety and depression scale (0-7 points are normal, 8- A score of 10 is borderline, 11 and above indicates abnormality).\n\nExclusion Criteria:\n\n* Women who did not meet the inclusion criteria, refused to participate in the study, and participated in less than 80% of the research practices (It is recommended to participate in at least 6 out of 8 sessions in the literature (Liu et al. 2022).),\n* Women who use mindfulness therapy, laughter therapy or any complementary or integrative medicine in their daily lives outside the research, women who have a diagnosed psychological disease, metastasis or recurrence, and whose chemotherapy treatment was terminated before the study was completed,\n* Women with stage 3 and stage 4 breast cancer, women who have been receiving chemotherapy for more than 1 year, women whose scores are 8 or below on the Hospital anxiety and depression scale (0-7 points indicate normal, 8-10 points indicate borderline, 11 and above indicate abnormality ).","60 Years",{"count":171,"type":21},105,[24],"Breast cancer is defined as the most common type of cancer that causes death among women (Siegel et al. 2019). It constitutes 24% of cancers and 15% of cancer-related deaths in women (T.R. Ministry of Health 2020). According to statistics made towards the end of 2020, there are 7.8 million women in the world who were diagnosed with breast cancer in the last 5 years and are alive. It is estimated that one in every 8 women will develop breast cancer in developed countries (WHO 2021).\n\nThe Ministry of Health reported the frequency of breast cancer in our country as 45.6\u002F100,000 in women in 2018. The incidence of breast cancer is reported to be higher, especially in the 45-54 age range (TC Ministry of Health 2020).\n\nChemotherapy is one of the most frequently preferred treatment methods in the treatment of breast cancer and can cause serious side effects such as pain, nausea and vomiting, loss of appetite, shortness of breath, mouth sores, fatigue, insomnia, anxiety and depression, and may lead to a deterioration in the quality of life of patients (Waks and Winer 2019, Samami et al. 2021, Sajadian et al. 2017, McFarland et al. 2018, Hamer et al. 2017).\n\nIn the international and national literature, no study has been found comparing the effects of laughter and mindfulness therapy on the anxiety, depression, quality of life and spiritual well-being experienced by breast cancer patients. In this study, it is planned to investigate the effects of laughter and mindfulness therapy applications on the anxiety, depression, quality of life and spiritual well-being levels of women with breast cancer receiving chemotherapy.",[175,176,177,178,27,179],"Breast Cancer","Laughter Therapy","Mindfulness Therapy","Life Quality","Spiritual Well-being","2024-08-11",{"date":182,"type":39},"2024-08-14",{"date":184,"type":39},"2024-01-01",{"date":186,"type":21},"2024-09-01",{"name":188,"class":46},"Kafkas University"]